- Home
- HYNE vs TKNO Comparison
HYNE vs TKNO Comparison
Compare HYNE & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HYNE | TKNO |
|---|---|---|
| Founded | 2025 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.5M | 138.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HYNE | TKNO |
|---|---|---|
| Price | $14.39 | $2.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.8K | ★ 131.6K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $40,520,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | N/A | $13.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.35 |
| 52 Week Low | $13.56 | $1.91 |
| 52 Week High | $14.90 | $7.48 |
Technical Indicators
Market Signals| Indicator | HYNE | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 53.35 | 49.36 |
| Support Level | $13.96 | $1.97 |
| Resistance Level | $14.81 | $5.39 |
| Average True Range (ATR) | 0.38 | 0.25 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 68.75 | 34.55 |
Price Performance
Historical ComparisonAbout HYNE Hoyne Bancorp Inc.
Hoyne Bancorp Inc is a holding company that conducts business mainly through its subsidiaries. It is a savings institution focused on serving customers' banking needs in the market area. The group offers Personal and Business banking services.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.